{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:16:41Z","timestamp":1788265001792,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neo.2026.101351","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:09:03Z","timestamp":1787011743000},"page":"101351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib following omeprazole preconditioning in KRAS G12C-mutant non-small cell lung cancer cells in vitro and in a mouse tumor xenograft"],"prefix":"10.1016","volume":"80","author":[{"given":"J\u00e8ssica","family":"Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebl","family":"Rou\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Val\u00e8ncia-Clua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Olmo-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Gonz\u00e1lez-Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloisa","family":"Jantus-Lewintre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gim\u00e9nez-Capit\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Molina-Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Codony-Servat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neo.2026.101351_bib0001","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-15-1105","article-title":"Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive State","volume":"6","author":"Patricelli","year":"2016","journal-title":"Cancer Discov."},{"issue":"15","key":"10.1016\/j.neo.2026.101351_bib0002","doi-asserted-by":"crossref","first-page":"15386","DOI":"10.1021\/acs.jmedchem.4c03183","article-title":"Discovery of Fulzerasib (GFH925) for the treatment of KRAS G12C-mutated solid tumors","volume":"68","author":"Jiang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.neo.2026.101351_bib0003","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1470-2045(25)00764-8","article-title":"Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b\/2 trial","volume":"27","author":"Gregorc","year":"2026","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.neo.2026.101351_bib0004","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-026-02998-z","article-title":"Cetuximab co-treatment with KRAS G12C inhibitors fulzerasib and sotorasib in human KRAS G12C non-small cell lung cancer cells","volume":"12","author":"Olmo-Gonz\u00e1lez","year":"2026","journal-title":"Cell Death Discov."},{"issue":"7790","key":"10.1016\/j.neo.2026.101351_bib0005","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","article-title":"Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition","volume":"577","author":"Xue","year":"2020","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.neo.2026.101351_bib0006","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s43018-023-00575-2","article-title":"Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS","volume":"4","author":"Adachi","year":"2023","journal-title":"Nat. Cancer"},{"issue":"3","key":"10.1016\/j.neo.2026.101351_bib0007","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/cas.16441","article-title":"Mechanisms of resistance to KRAS inhibitors: cancer cells' Strategic use of normal cellular Mechanisms to adapt","volume":"116","author":"Tanaka","year":"2025","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.neo.2026.101351_bib0008","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in Human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"issue":"25","key":"10.1016\/j.neo.2026.101351_bib0009","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10378","key":"10.1016\/j.neo.2026.101351_bib0010","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.neo.2026.101351_bib0011","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1038\/s41591-025-03732-5","article-title":"Molecular determinants of sotorasib clinical efficacy in KRAS(G12C)-mutated non-small-cell lung cancer","volume":"31","author":"Skoulidis","year":"2025","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.neo.2026.101351_bib0012","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrm2410","article-title":"Spatial and temporal coordination of mitosis by Ran GTPase","volume":"9","author":"Clarke","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"12","key":"10.1016\/j.neo.2026.101351_bib0013","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/s43018-024-00847-5","article-title":"The pro-oncogenic noncanonical activity of a RAS\u2022GTP:ranGAP1 complex facilitates nuclear protein export","volume":"5","author":"Tripathi","year":"2024","journal-title":"Nat. Cancer"},{"issue":"1","key":"10.1016\/j.neo.2026.101351_bib0014","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41420-026-03080-4","article-title":"AURKA\/PHB2 signaling drives acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant NSCLC","volume":"12","author":"Liao","year":"2026","journal-title":"Cell Death Discov."},{"issue":"3","key":"10.1016\/j.neo.2026.101351_bib0015","article-title":"Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.neo.2026.101351_bib0016","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/1535-7163.MCT-13-0416","article-title":"XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer","volume":"13","author":"Cheng","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.neo.2026.101351_bib0017","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/bjc.2014.260","article-title":"KPT-330 has antitumour activity against non-small cell lung cancer","volume":"111","author":"Sun","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"7623","key":"10.1016\/j.neo.2026.101351_bib0018","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature19771","article-title":"XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer","volume":"538","author":"Kim","year":"2016","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.neo.2026.101351_bib0019","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2767-9764.CRC-21-0176","article-title":"Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C-mutant cancers","volume":"2","author":"Khan","year":"2022","journal-title":"Cancer Res. Commun."},{"issue":"1","key":"10.1016\/j.neo.2026.101351_bib0020","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12964-024-01667-x","article-title":"KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination","volume":"22","author":"Rosell","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.neo.2026.101351_bib0021","article-title":"AURKA\/PHB2 signaling drives acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant NSCLC","author":"Liao","year":"2026","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.neo.2026.101351_bib0022","article-title":"AURKA suppresses NCOA4-mediated ferritinophagy to enhance sorafenib resistance in hepatocellular carcinoma","author":"Zhu","year":"2026","journal-title":"Cell Death Disease."},{"issue":"6662","key":"10.1016\/j.neo.2026.101351_bib0023","doi-asserted-by":"crossref","first-page":"eabn4180","DOI":"10.1126\/science.abn4180","article-title":"Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors","volume":"381","author":"Lv","year":"2023","journal-title":"Science"},{"issue":"null","key":"10.1016\/j.neo.2026.101351_bib0024","first-page":"55","article-title":"HMGB1 Expression levels correlate with response to immunotherapy in non-small cell lung cancer","volume":"15","author":"Gonz\u00e1lez-Cao","year":"2024","journal-title":"Lung Cancer: Targ. Ther."},{"issue":"7269","key":"10.1016\/j.neo.2026.101351_bib0025","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.neo.2026.101351_bib0026","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.jtho.2017.06.013","article-title":"Therapeutic targeting of nuclear export inhibition in lung cancer","volume":"12","author":"Gupta","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.neo.2026.101351_bib0027","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.neo.2026.101351_bib0028","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1158\/1535-7163.MCT-17-0789-ATR","article-title":"XPO1 Inhibitor selinexor overcomes intrinsic ibrutinib resistance in mantle cell lymphoma via nuclear retention of I\u03baB","volume":"17","author":"Ming","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.neo.2026.101351_bib0029","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-022-01319-y","article-title":"Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents","volume":"15","author":"Lee","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.neo.2026.101351_bib0030","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7150\/ijbs.66612","article-title":"Verdinexor, a selective inhibitor of nuclear exportin 1, inhibits the proliferation and migration of esophageal cancer via XPO1\/c-Myc\/FOSL1 axis","volume":"18","author":"Ou","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"4","key":"10.1016\/j.neo.2026.101351_bib0031","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1158\/1078-0432.CCR-24-1722","article-title":"Phase I\/II trial of Exportin 1 inhibitor Selinexor plus Docetaxel in previously treated, advanced KRAS-mutant non-small cell lung cancer","volume":"31","author":"von Itzstein","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.neo.2026.101351_bib0032","article-title":"Parallel phase II clinical trials of Selinexor in patients with advanced thymoma and thymic carcinoma","volume":"6","author":"Kim","year":"2025","journal-title":"JTO Clin. Res. Rep."},{"issue":"6","key":"10.1016\/j.neo.2026.101351_bib0033","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2159-8290.CD-25-1616","article-title":"Abrogation of oncogenic RAS signaling by a RAS(ON) inhibitor doublet primes immune-refractory KRASG12C-mutant NSCLC for Immune checkpoint blockade","volume":"16","author":"Wei","year":"2026","journal-title":"Cancer Discov."},{"issue":"834","key":"10.1016\/j.neo.2026.101351_bib0034","doi-asserted-by":"crossref","first-page":"eadx6873","DOI":"10.1126\/scitranslmed.adx6873","article-title":"SREBP-1 increases glucose uptake to promote tumor resistance to lysosome inhibition","volume":"18","author":"Zhong","year":"2026","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.neo.2026.101351_bib0035","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2026.01.001","article-title":"Emerging landscape of KRAS inhibitors in cancer treatment","volume":"44","author":"Riedl","year":"2026","journal-title":"Cancer Cell."},{"issue":"4","key":"10.1016\/j.neo.2026.101351_bib0036","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2605555","article-title":"Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer","volume":"395","author":"O'Reilly","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2026.101351_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1380584","article-title":"KRAS G12C inhibitor combination therapies: current evidence and challenge","volume":"14","author":"Miyashita","year":"2024","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.neo.2026.101351_bib0038","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/2159-8290.CD-25-0349","article-title":"Response and resistance to RAS inhibition in cancer","volume":"15","author":"Ebright","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.neo.2026.101351_bib0039","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-026-48898-1","article-title":"Expression of LIFR in tumor and SHOC2, YAP1 in plasma mRNA as potential biomarkers in KRAS (G12C) NSCLC","volume":"16","author":"Gim\u00e9nez-Capit\u00e1n","year":"2026","journal-title":"Sci. Rep."},{"issue":"8013","key":"10.1016\/j.neo.2026.101351_bib0040","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","article-title":"Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer","volume":"629","author":"Wasko","year":"2024","journal-title":"Nature"},{"issue":"707","key":"10.1016\/j.neo.2026.101351_bib0041","doi-asserted-by":"crossref","first-page":"eadf7006","DOI":"10.1126\/scitranslmed.adf7006","article-title":"Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers","volume":"15","author":"Quintanal-Villalonga","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.neo.2026.101351_bib0042","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s43018-022-00394-x","article-title":"P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia","volume":"3","author":"Lin","year":"2022","journal-title":"Nat. Cancer"},{"issue":"4","key":"10.1016\/j.neo.2026.101351_bib0043","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1158\/1078-0432.CCR-18-2297","article-title":"Targeting purinergic receptor P2Y2 prevents the growth of pancreatic ductal adenocarcinoma by inhibiting cancer cell glycolysis","volume":"25","author":"Hu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2026.101351_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108073","article-title":"Targeting XPO1 for fighting relapsed\/refractory diseases: the research progress of XPO1 inhibitors","volume":"154","author":"Li","year":"2025","journal-title":"Bioorg. Chem."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626000825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626000825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:38:11Z","timestamp":1788262691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558626000825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"alternative-id":["S1476558626000825"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2026.101351","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib following omeprazole preconditioning in KRAS G12C-mutant non-small cell lung cancer cells in vitro and in a mouse tumor xenograft","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2026.101351","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101351"}}